Kytril (Granisetron)

Granisetron selectively antagonizes serotonin (5‑HT3) receptors located in the chemoreceptor trigger zone of the brain and in the vagal afferents of the gastrointestinal tract. By blocking these receptors, it prevents serotonin‑mediated activation of the vomiting reflex, thereby reducing both acute and delayed nausea and vomiting. Its action is confined to the 5‑HT3 pathway without affecting other neurotransmitter systems.

The dosage of Kytril is individualized by the prescribing clinician based on the patient’s treatment regimen, severity of nausea, and renal or hepatic function. Typical regimens may involve a single oral tablet taken before chemotherapy or surgery, with possible repeat dosing for delayed symptoms. Exact dosing instructions must be obtained from a qualified healthcare provider.

Safety data for granisetron in pregnancy and lactation are limited. It is classified as a pregnancy category where use is only recommended if the potential benefit justifies the potential risk to the fetus. Granisetron is excreted in breast milk, so nursing mothers should consult their physician before using Kytril.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Kytril. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifying trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Both Kytril (granisetron) and ondansetron are 5‑HT3 receptor antagonists used to prevent chemotherapy‑induced and postoperative nausea. Granisetron has a longer half‑life, allowing once‑daily dosing, whereas ondansetron often requires multiple daily doses. Their safety profiles are similar, though individual patient response and tolerability may differ, making clinician choice dependent on specific clinical circumstances.

Kytril tablets should be stored at room temperature, below 25 °C, in their original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children. Do not store in areas with high humidity or extreme temperatures, as these conditions may affect tablet stability.

Kytril is administered orally as a tablet. The tablet is swallowed whole with a glass of water, typically 30 minutes before the start of chemotherapy or surgery. It should not be crushed, chewed, or dissolved unless specifically directed by a healthcare professional. Oral administration provides systemic absorption sufficient to block peripheral and central 5‑HT3 receptors.

The most serious adverse reactions to Kytril include cardiac arrhythmias such as QT interval prolongation, which can lead to torsades de pointes, and severe hypersensitivity reactions like anaphylaxis. Patients with existing cardiac conduction disorders or those taking other QT‑prolonging drugs should be monitored closely. Immediate medical attention is required if symptoms of serious cardiac or allergic reactions occur.

Kytril should be avoided in patients with known hypersensitivity to granisetron or any component of the tablet formulation. Caution is advised for individuals with a history of prolonged QT interval, significant cardiac disease, or those receiving concurrent medications that also prolong the QT interval. Pregnant or breastfeeding women should only use it when clearly indicated by a physician, after weighing potential risks and benefits.